Low TMB as predictor for additional benefit from neoadjuvant immune checkpoint inhibition in triple-negative breast cancer.
暂无分享，去创建一个
A. Schneeweiss | C. Denkert | S. Loibl | K. Weber | P. Jank | M. Untch | J. Huober | W. Schmitt | T. Karn | C. Jackisch | C. Schem | C. Hanusch | E. Stickeler | U. Holtrich | B. Sinn | J. Rey | M. V. van Mackelenbergh | J. Blohmer